CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

Roflumilast

Last Updated: November 30, 2010
Result type: Reports
Project Number: S0218
Product Line: Reimbursement Review

Generic Name: Roflumilast

Brand Name: Daxas

Manufacturer: Nycomed Canada Inc.

Indications: Chronic obstructive pulmonary disease (COPD)

Submission Type: Initial

Project Status: Complete

Date Recommendation Issued: July 27, 2011

Recommendation Type: Do not list